Compare MMI & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMI | IOVA |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 968.6M |
| IPO Year | 2013 | N/A |
| Metric | MMI | IOVA |
|---|---|---|
| Price | $28.15 | $2.46 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $29.00 | $10.45 |
| AVG Volume (30 Days) | 440.2K | ★ 10.2M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $751,284,000.00 | $250,425,000.00 |
| Revenue This Year | $11.94 | $60.94 |
| Revenue Next Year | $15.59 | $60.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 20.74 | ★ 175.62 |
| 52 Week Low | $27.35 | $1.64 |
| 52 Week High | $41.94 | $8.15 |
| Indicator | MMI | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 57.65 |
| Support Level | $27.38 | $2.08 |
| Resistance Level | $28.99 | $2.32 |
| Average True Range (ATR) | 0.82 | 0.14 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 33.05 | 73.08 |
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.